NEW YORK, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Nilo Therapeutics, a biotechnology company harnessing neural circuits to restore immune homeostasis in disease, launched today with a $101 million Series A financing led by The Column Group (TCG), DCVC Bio, and Lux Capital, with participation from the Gates Foundation and Alexandria Venture Investments. Coinciding with its launch, Nilo announced the appointment of Kim Seth, Ph.D., as Chief Executive Officer and Board director.

Founded by world-leading scientists Charles Zuker, Ph.D. (Columbia University), Ruslan Medzhitov, Ph.D. (Yale University), and Steve Liberles, Ph.D. (Harvard University), Nilo was created in collaboration with TCG to translate groundbreaking scientific insights in neuro-immunology into new therapeutic strategies. Dr. Seth joins Chief Scientific Officer Laurens Kruidenier, Ph.D., in leading the company's transition from stealth into its next stage of growth. The financing fuels the establishment of Nilo's laboratories in New York City, growth of its interdisciplinary research and development team, and advancement of the company's preclinical programs.

Nilo is developing drugs that harness neural circuits to restore immune homeostasis centrally, offering a differentiated approach to immunomodulation and moving beyond conventional immunosuppression. The company builds on seminal scientific discoveries from the laboratory of Charles Zuker, Ph.D. (Columbia University Principal Investigator and Howard Hughes Medical Institute Investigator), which identified specific vagal neurons that regulate systemic immune activation and inflammation. By targeting these central "master regulator" brain-body circuits, Nilo is employing its novel therapeutic approach ...